| Overview |
| bsm-61910r-100ul |
| ILF3 Recombinant Antibody |
| WB, FCM, IHC-P, IHC-F, IF(IHC-P), IF(ICC), IP |
| Human, Mouse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ILF3 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 3609 |
| Q12906 |
| Nucleus |
| CBTF; DRBF; MMP4; MPP4; NF90; NFAR; NF110; NF90a; NF90b; NFAR2;TCP80; DRBP76; NF110b; NFAR-1; TCP110; MPHOSPH4; NF-AT-90. |
| May facilitate double-stranded RNA-regulated gene expression at the level of post-transcription. Can act as a translation inhibitory protein which binds to coding sequences of acid beta-glucosidase (GCase) and other mRNAs and functions at the initiation phase of GCase mRNA translation, probably by inhibiting its binding to polysomes. |
| Application Dilution |
| WB |
1:500-2000 |
| FCM |
FCM1:50-100 |
| IHC-P |
IHC-P1:100-500 |
| IHC-F |
IHC-F1:100-500 |
| IF(IHC-P) |
IFIHC-P1:100-500 |
| IF(ICC) |
IFICC1:50-200 |
| IP |
IP1:20-50 |